Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
CHOLOGRAFIN MEGLUMINE vs DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent